STOCK TITAN

[Form 4] ABBOTT LABORATORIES Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Patricia Paola Gonzalez, a director of Abbott Laboratories (ABT), had a non-derivative transaction on 09/30/2025 that credited 246 stock equivalent units at an indicated per-share reference of $133.94. After the reported transaction, the filing shows she beneficially owned 4,922 shares/stock-equivalent units. The filing explains these credits represent director fees placed into a stock equivalent unit account under a director grantor trust, which are paid in cash generally at age 65 or upon retirement from the board and earn the same return as if invested in Abbott shares. The reported Form 4 was signed via attorney-in-fact on 10/02/2025.

Patricia Paola Gonzalez, una di Abbott Laboratories (ABT), ha effettuato una operazione non derivativa il 30/09/2025 che ha attribuito 246 unità azionarie equivalenti al riferimento indicato per ogni azione di $133,94. Dopo l’operazione riportata, la documentazione mostra che possedeva di fatto 4.922 azioni/unita equivalenti azionari. La documentazione spiega che questi crediti rappresentano onorari da direttore versati in un conto di unità azionarie equivalenti sotto un trust grantor per direttori, che vengono pagati in contanti tipicamente all’età di 65 anni o al momento del ritiro dal consiglio e hanno lo stesso rendimento di un investimento in azioni Abbott. Il Form 4 riportato è stato firmato tramite procuratore-in-fatto il 02/10/2025.

Patricia Paola Gonzalez, una directora de Abbott Laboratories (ABT), tuvo una operación no derivada el 30/09/2025 que acreditó 246 unidades de stock equivalentes a un referencia por acción indicado de $133,94. Después de la operación reportada, la documentación muestra que poseía de forma beneficiosa 4.922 acciones/unidades equivalentes de stock. La documentación explica que estos créditos representan honorarios de directora depositados en una cuenta de unidades equivalentes de stock bajo un fideicomiso de otorgamiento para directores, que se pagan en efectivo normalmente a la edad de 65 años o al retirarse de la junta y obtienen el mismo rendimiento que si se invirtieran en acciones de Abbott. El Formulario 4 reportado fue firmado por apoderado el 02/10/2025.

Patricia Paola GonzalezAbbott Laboratories (ABT)이사로서 비파생거래2025-09-30에 체결했고, 이는 246 주의 등가 단위를 주당 지시된 참조가 $133.94인 것으로 적립했습니다. 보고된 거래 후 서류에 따르면 그녀는 실질적으로 4,922 주/주당 등가 단위를 보유하고 있습니다. 서류는 이 크레딧이 이사 수수료를 이사 수여 신탁 하의 주식 등가 단위 계좌에 예치한 것이며, 일반적으로 만 65세에 현금으로 지급되거나 이사회에서 은퇴할 때 지급되며 Abbott 주에 투자했을 때와 같은 수익을 얻는다고 설명합니다. 보고된 Form 4는 2025-10-02에 대리인에 의해 서명되었습니다.

Patricia Paola Gonzalez, une directrice de Abbott Laboratories (ABT), a effectué une opération non dérivée le 30/09/2025 qui a crédité 246 unités d’actifs équivalentes à un référence par action indiquée de $133,94. Après l’opération signalée, le dossier indique qu’elle détenait avantageusement 4 922 actions/unités équivalentes. Le dossier explique que ces crédits représentent des honoraires de directrice placés dans un compte d’unités équivalentes sous une fiducie de donateur-directeur, qui sont payés en espèces généralement à l’âge de 65 ans ou lors de la retraite du conseil et rapportent le même rendement que s’ils avaient été investis dans des actions Abbott. Le Formulaire 4 signalé a été signé via mandataire le 02/10/2025.

Patricia Paola Gonzalez, eine Direktorin von Abbott Laboratories (ABT), hatte am 30.09.2025 eine nicht-derivative Transaktion, die 246 Aktienäquivalenteinheiten bei einem angegebenen Bezug von 133,94 USD pro Aktie gutgeschrieben hat. Nach der gemeldeten Transaktion zeigte die Einreichung, dass sie wirtschaftlich tätig 4.922 Anteile/Aktienäquivalente besaß. Die Einreichung erklärt, dass diese Guthaben Direktorengehälter darstellen, die in ein Aktienäquivalenzeinlagenkonto unter einem Direktorenzuwendungsfonds eingezahlt werden, das in der Regel bei 65 Jahren oder bei Ausscheiden aus dem Vorstand in Bar ausgezahlt wird und die gleiche Rendite erzielt wie eine Investition in Abbott-Aktien. Das gemeldete Formular 4 wurde am 02.10.2025 durch Bevollmächtigten unterzeichnet.

Patricia Paola Gonzalez، مديرة في Abbott Laboratories (ABT)، قامت بعملية غير مشتقة في 30/09/2025 اعتمدت 246 وحدة من الأسهم المعادلة عند مرجع السهم المقدر ب
$133.94. بعد العملية المذكورة، تُبيّن المستندات أنها كانت تملك فعلياً 4,922 سهم/وحدات أسهم معادلة. تشرح المستندات أن هذه الاعتمادات تمثل أتعاب مدير تُودع في حساب وحدات الأسهم المعادلة تحت ائتمان مانح مدير، وتُدفع نقداً عادة عند بلوغ 65 عاماً أو عند التقاعد من المجلس وتحقق العائد نفسه كما لو استُثمرت في أسهم Abbott. وتم توقيع النموذج 4 المبلغ عنه عبر وكيل-بالفعل في 02/10/2025.

Patricia Paola GonzalezAbbott Laboratories (ABT) 的一位董事,在2025/09/30有一笔非衍生交易,记入246股等价单位,按每股指示参考价$133.94。据申报后,该人实际拥有4,922股/等价单位。申报文件解释,这些记入代表将董事费用放入董事赠与信托之下的股票等价单位账户,通常在65岁或从董事会退休时以现金支付,且其回报与直接投资Abbott股票的回报相同。所申报的Form 4于2025/10/02由代理人签署。

Positive
  • Director compensation is tied to stock-equivalent units, aligning pay with shareholder returns
  • Dividend reinvestment feature is active, as balance includes units from dividends
Negative
  • None.

Patricia Paola Gonzalez, una di Abbott Laboratories (ABT), ha effettuato una operazione non derivativa il 30/09/2025 che ha attribuito 246 unità azionarie equivalenti al riferimento indicato per ogni azione di $133,94. Dopo l’operazione riportata, la documentazione mostra che possedeva di fatto 4.922 azioni/unita equivalenti azionari. La documentazione spiega che questi crediti rappresentano onorari da direttore versati in un conto di unità azionarie equivalenti sotto un trust grantor per direttori, che vengono pagati in contanti tipicamente all’età di 65 anni o al momento del ritiro dal consiglio e hanno lo stesso rendimento di un investimento in azioni Abbott. Il Form 4 riportato è stato firmato tramite procuratore-in-fatto il 02/10/2025.

Patricia Paola Gonzalez, una directora de Abbott Laboratories (ABT), tuvo una operación no derivada el 30/09/2025 que acreditó 246 unidades de stock equivalentes a un referencia por acción indicado de $133,94. Después de la operación reportada, la documentación muestra que poseía de forma beneficiosa 4.922 acciones/unidades equivalentes de stock. La documentación explica que estos créditos representan honorarios de directora depositados en una cuenta de unidades equivalentes de stock bajo un fideicomiso de otorgamiento para directores, que se pagan en efectivo normalmente a la edad de 65 años o al retirarse de la junta y obtienen el mismo rendimiento que si se invirtieran en acciones de Abbott. El Formulario 4 reportado fue firmado por apoderado el 02/10/2025.

Patricia Paola GonzalezAbbott Laboratories (ABT)이사로서 비파생거래2025-09-30에 체결했고, 이는 246 주의 등가 단위를 주당 지시된 참조가 $133.94인 것으로 적립했습니다. 보고된 거래 후 서류에 따르면 그녀는 실질적으로 4,922 주/주당 등가 단위를 보유하고 있습니다. 서류는 이 크레딧이 이사 수수료를 이사 수여 신탁 하의 주식 등가 단위 계좌에 예치한 것이며, 일반적으로 만 65세에 현금으로 지급되거나 이사회에서 은퇴할 때 지급되며 Abbott 주에 투자했을 때와 같은 수익을 얻는다고 설명합니다. 보고된 Form 4는 2025-10-02에 대리인에 의해 서명되었습니다.

Patricia Paola Gonzalez, une directrice de Abbott Laboratories (ABT), a effectué une opération non dérivée le 30/09/2025 qui a crédité 246 unités d’actifs équivalentes à un référence par action indiquée de $133,94. Après l’opération signalée, le dossier indique qu’elle détenait avantageusement 4 922 actions/unités équivalentes. Le dossier explique que ces crédits représentent des honoraires de directrice placés dans un compte d’unités équivalentes sous une fiducie de donateur-directeur, qui sont payés en espèces généralement à l’âge de 65 ans ou lors de la retraite du conseil et rapportent le même rendement que s’ils avaient été investis dans des actions Abbott. Le Formulaire 4 signalé a été signé via mandataire le 02/10/2025.

Patricia Paola Gonzalez, eine Direktorin von Abbott Laboratories (ABT), hatte am 30.09.2025 eine nicht-derivative Transaktion, die 246 Aktienäquivalenteinheiten bei einem angegebenen Bezug von 133,94 USD pro Aktie gutgeschrieben hat. Nach der gemeldeten Transaktion zeigte die Einreichung, dass sie wirtschaftlich tätig 4.922 Anteile/Aktienäquivalente besaß. Die Einreichung erklärt, dass diese Guthaben Direktorengehälter darstellen, die in ein Aktienäquivalenzeinlagenkonto unter einem Direktorenzuwendungsfonds eingezahlt werden, das in der Regel bei 65 Jahren oder bei Ausscheiden aus dem Vorstand in Bar ausgezahlt wird und die gleiche Rendite erzielt wie eine Investition in Abbott-Aktien. Das gemeldete Formular 4 wurde am 02.10.2025 durch Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Gonzalez Patricia Paola

(Last) (First) (Middle)
100 ABBOTT PARK ROAD

(Street)
ABBOTT PARK IL 60064

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Equivalent Units (1) 09/30/2025 A 246 (1) (1) Common Shares 246 $133.94 4,922(2) D
Explanation of Responses:
1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
/s/ Patricia Paola Gonzalez by Jessica H. Paik, Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Abbott director Patricia Gonzalez report on Form 4 (ABT)?

The Form 4 reports a 09/30/2025 credit of 246 stock equivalent units at a reference of $133.94 and a post-transaction beneficial ownership of 4,922 units.

How are the stock equivalent units for the director paid or settled?

The filing states director fees are credited to a stock equivalent unit account under a grantor trust and are paid in cash generally at age 65 or upon retirement from the board.

Do the stock equivalent units earn returns like Abbott shares?

Yes, the Form 4 explains the stock equivalent units earn the same return as if the fees were invested in Abbott shares.

Does the reported balance include dividend reinvestment?

Yes. The filing notes the balance of 4,922 includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

When was the Form 4 signed and who signed it?

The Form 4 was signed on behalf of Patricia Paola Gonzalez by an attorney-in-fact, with the signature dated 10/02/2025.
Abbott Labs

NYSE:ABT

ABT Rankings

ABT Latest News

ABT Latest SEC Filings

ABT Stock Data

231.46B
1.73B
0.54%
80.8%
1.02%
Medical Devices
Pharmaceutical Preparations
Link
United States
ABBOTT PARK